| Name | Title | Contact Details |
|---|
Located in northern California, Consensus Orthopedics is committed to providing proven and reliable total joint implants and instruments to the global market. Consensus headquarters include administrative offices, research and design workrooms, manufacturing, inspection, clean room and warehouse space. With over 25 years of orthopedic design and manufacturing experience, together, through a focus on patient care and clinician relationships, Consensus is dedicated to creating one team, focused on restoring mobility and renewing lives.
Cardinal Health Canada is a Concord, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Novera Drugs is a Louisville, KY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Augmedics develops xvision™ – an Augmented-Reality Head-Mounted Display for spine surgery. xvision allows surgeons to see the patient`s anatomy through skin and tissue, as if they had "X-Ray Vision". Based on Augmedics` patented technology, the xvision system can project the patient`s anatomy, in real time, directly onto the surgeon`s retina, with surgical precision and outstanding depth perception. xvision will increase safety in surgery, reduce x-ray radiation, and facilitate minimally invasive procedures.
Motif Neurotech is a clinical-stage company leading the development of minimally invasive neuromodulation therapeutics for mental health. The company`s lead product, for treatment resistant depression (TRD), is a miniature implant that is designed to treat TRD by increasing activity in the prefrontal cortex. Studies over 20 years show stimulation of the pre-frontal cortex effectively treats treatment resistant depression without the side effects of anti-depressants. However, existing brain stimulation treatments like transcranial magnetic stimulation (TMS) can be expensive and challenging for patients to access, with daily treatments required for six weeks that may need to be repeated. Human and large animal studies show Motif`s prototype stimulates target brain areas like TMS, and the company is preparing to begin clinical trials of their first chronic implants in 2025. Motif`s implant is enabled by patent-pending wireless magnetoelectric power transfer developed at Rice University. Motif`s founders and key team members are clinical, medical device and academic experts with over 5,000 surgical procedures and decades of medical device experience.